Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, November 13, 2018
GenomOncology was selected by the Indiana University School of Medicine to utilize GO's proprietary match algorithm and GO's extensive KMS API suite to provide real-time clinical trial recommendations to clinical researchers for the benefit of IU ...
read more
Wednesday, December 26, 2018
GenomOncology announced today that Brad Wertz will assume the role of Chairman and Chief Executive Officer (CEO) as of January 1, 2019.
read more
Genomma Lab has announced the Mexican Federal COFEPRIS has granted the Sanitary License which permits the Company's new manufacturing facility to begin operations.
read more
Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design. ...
read more
Thursday, January 23, 2020
Genome & Company has entered into a clinical trial collaboration and supply agreement with Merck KGaA and Pfizer to evaluate GEN-001 therapy in combination with avelumab.
read more
GenNext Technologies, Inc., is collaborating with Emery Pharma, a full-service CRO offering end-to-end biologic drug development support.
read more
Thursday, August 03, 2023
GENIXUS announced the accelerated development and launch* of the latest product within their KinetiX syringe platform: Rocuronium Bromide Injection.
read more
Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and a leader in pediatric research, and Genezen, a gene and cell therapy contract development and manufacturing organization, have unveiled a strategic ...
read more
Monday, December 06, 2021
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially opened its new process development and ...
read more
Wednesday, October 12, 2022
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, has completed another expansion phase at its viral vector process development and cGMP vector ...
read more
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master...
read more
Genezen Laboratories Inc. a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has further strengthened its senior leadership team with the appointment of Brok Weichbrodt as Vice President of Operations.
read more
Tuesday, January 25, 2022
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, GMP vector production and analytical testing services, has appointed Laura Jacanin as Senior Director of ...
read more
Thursday, December 01, 2022
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, continues to scale and expand its commercial operations with the appointment of Jeff Whitmore ...
read more
Thursday, November 13, 2025
Genezen and Humane announced a partnership for process transfer and cGMP manufacturing of HGI627, a novel therapy targeting pediatric liver cancer (hepatoblastoma).
read more